Coiled-coil domain-containing protein 69 (CCDC69)

Coiled-coil domain-containing protein 69 (CCDC69) is a cytoplasmic protein characterized by a coiled-coil structural motif that enables it to participate in a variety of protein-protein interactions[2][4]. It plays a central role in cell cycle progression, especially in the assembly of the central spindle and recruitment of midzone components required for cytokinesis[2]. CCDC69 influences apoptosis, particularly enhancing the cytotoxic effect of platinum-based chemotherapy in ovarian cancer[2]. In cancer, its expression is typically downregulated; higher expression correlates with improved prognosis in breast cancer and may enhance the immune response to checkpoint inhibitor therapies[2][4]. It is thus considered an emerging prognostic biomarker and may inform both immunotherapy and chemotherapy strategies, but there is no evidence it directly interacts with any approved drugs or functions as a classic pharmacological target (such as a receptor or enzyme)[2][4]. Key points: - CCDC69 is not a membrane-bound receptor, enzyme, ion channel, or traditional drug target; its therapeutic relevance is primarily as a prognostic and predictive biomarker in cancer, especially breast cancer, but it is not currently considered a direct therapeutic target[2][4]. - No approved drugs are known to bind to or modulate CCDC69 directly, and there are no established mechanisms of action for pharmacological targeting of this protein[2][4].

Other names

FLJ13705DKFZP434C171coiled-coil domain containing 69coiled-coil domain-containing protein 69